MedTrace Logo

Biotherapy Treatment on Features of Microcrystalline Polyarthritis

NCT04005625 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 46

Last updated 2020-09-14

No results posted yet for this study

Summary

The study will involve adult patient who had received any biologic agent for microcrystalline disease in western France (Tours, Le Mans, Orléans, Angers, Rennes, Poitiers et Brest) between 01/01/2010 and 31/12/2018.

Investigators will answer retrospectively a questionnaire that covers patient and disease data, biologic agent use, efficacy and adverse events.

Conditions

  • Crystal-Induced Arthritis

Sponsors & Collaborators

  • University Hospital, Brest

    lead OTHER

Principal Investigators

  • Alain SARAUX, MD, PhD · CHU Brest

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-01
Primary Completion
2020-06-01
Completion
2020-06-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04005625 on ClinicalTrials.gov